IDO1 and cancer: The results in our study were complied with above findings, adding fundamental evidences to the combination of IDO1 inhibition and IC blockage for cancer treatment, though the much-anticipated phase III clinical trial (ECHO-301/KEYNOTE-252) of IDO1 inhibitor compound 29 combined with PD-1 inhibitor failed (Long et al., 2019).